biopharmaceutical

Axsome Therapeutics will report first-quarter 2026 financial results on May 4, 2026, with management conference call at 8:00 a.m. ET.

OKYO Pharma presents Phase 2 urcosimod data at ASCRS conference; plans Phase 2b/3 trial launch in H1 2026 for neuropathic corneal pain.

Oculis announces investor conference participation ahead of landmark 2026 featuring multiple drug readouts and regulatory designations across three lead programs.

Pharming Group schedules April 2026 investor conferences following positive CHMP opinion for Joenja® leniolisib in APDS treatment.

Geron Corporation will discuss its commercial-stage telomerase inhibitor platform at the Needham Healthcare Conference on April 13, highlighting RYTELO® adoption and ongoing Phase 3 trials in myelofibrosis.

Rhythm Pharmaceuticals appoints veteran life sciences executive Kim Popovits to board, replacing Ed Mathers after decade-long tenure.

Kura Oncology granted 153,750 stock options at $8.34/share to six new employees under Nasdaq Rule 5635(c)(4), valued at approximately $1.28 million, with standard four-year vesting.

ADMA Biologics under fraud investigation after Culper Research alleged channel stuffing masked -3% actual revenue decline reported as +20% growth, causing 29% stock collapse.

NewAmsterdam Pharma grants 15,000 options and 3,200 RSUs to two new executives, complying with Nasdaq listing regulations.

Telix Pharmaceuticals appoints experienced life sciences executive David Gill as Non-Executive Director, with planned succession to Chair role, bringing 35+ years of CFO and commercial expertise.

Ardelyx appoints Dr. Rajani Dinavahi, veteran biotech executive from Amgen and Atara Biotherapeutics, as Chief Medical Officer to lead clinical strategy and pipeline advancement.

Galmed files 2025 annual report detailing Aramchol development for NASH and cardiometabolic diseases, including clinical trial progress and regulatory disclosures.

Soligenix reported zero 2025 revenue and $11.1M net loss. Company has $7.9M cash, seeking partnerships to fund operations through Q4 2026 pivotal trials.

Teva gains FDA approval for denosumab biosimilar PONLIMSI and achieves dual filing acceptance for omalizumab candidate, bolstering its biosimilars portfolio.

ADMA Biologics shares crashed 16% after short seller accused the company of inflating revenues through improper rebates and extended payment terms to distributors.

Quantum BioPharma grants 35,000 stock options to employees at CA$6.50 strike, vesting immediately with five-year exercise window.

Werewolf Therapeutics seeks strategic alternatives including potential sale or merger. Company reports improved 2025 financials, reduced losses, and $57.1M cash reserves.

Zenas BioPharma prices $300M offering combining $200M convertible notes and 5M common shares to fund obexelimab launch and pipeline advancement.

Clinical-stage biotech Sitryx Therapeutics will present at four investor conferences in April 2026, highlighting its oral autoimmune and inflammatory disease therapies.

Kamada Ltd. gains FDA approval for its San Antonio plasma collection center, expected to generate $8-10 million annually at full capacity.